Skip to main content

Dr. David I. Bernstein, M.D.

Allergy & Immunology (Allergy & Immunology Physician)

  • Medicare participating

Medicare and federal program status

Opted out of Medicare from May 22, 2025 through May 22, 2027. Medicare does not pay for this clinician’s services: patients with Medicare sign a private contract and pay the clinician directly. They can still order tests and refer Medicare patients to other providers.

Source: CMS Medicare Opt Out Affidavits (record last updated July 15, 2025). Opting out is a legal choice many clinicians make, often to run a cash or concierge practice.

At a glance

In the NPI registry since
2005
Medicare patients seen, 2024
139

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Allergy & Immunology Physician primary
    OH license 35043186
  • Clinical & Laboratory Immunology (Internal Medicine) Physician
    OH license 35 043186
  • Internal Medicine Physician
    OH license 35 043186

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Allergy & Immunology per capita by county →

Medicare patients and services

Medicare patients, 2024
139
Services billed
458
Patients’ average age
72
Most frequent Medicare services, 2023
ServiceTimesPatients
Test for allergy using allergenic extract23613
Established patient office or other outpatient visit, 30-39 minutes11673
Established patient office or other outpatient visit, 20-29 minutes6252
Professional service for multiple injections of allergen6216
New patient office or other outpatient visit, 45-59 minutes4343
Test to measure expiratory airflow and volume2121
Test to measure the level of nitric oxide gas1313

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 17 companies reported 40 payments worth $3,209 in total to this clinician.

By company
Genzyme Corporation$2,448
Stryker Corporation$212
Novartis Pharmaceuticals Corporation$153
Biocryst US Sales Co., LLC$51.00
Blueprint Medicines Corporation$48.00
Azurity Pharmaceuticals, Inc.$41.59
AstraZeneca Pharmaceuticals LP$34.46
Leo Pharma Inc.$28.95
By type
Consulting Fee$2,092
Food and Beverage$1,117

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Apr 2, 2025Genzyme Corporation
Apr 2, 2025
Consulting Fee$2,070
Feb 4, 2025Adma Biomanufacturing LLC
Feb 4, 2025
Consulting Fee$18.35
Jan 1, 2025Adma Biomanufacturing LLC
Jan 1, 2025
Consulting Fee$4.00

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Ohio →

Industry-funded research

Named as a principal investigator on 10 industry-funded studies in 2025, from 7 companies. The companies reported $405,095 in research payments for these studies, mostly to the institutions running them.

  • Characterization of hsv inhibitors in the HSV2 guinea pig model of infection
    Pfizer Inc.
  • A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared …
    AstraZeneca Pharmaceuticals LP
  • A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in…
    Teva Pharmaceuticals USA, Inc.
  • A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
    Eli Lilly and Company · Active, not recruiting · NCT06339008
  • A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
    Amgen Inc.
  • A multi-centre, single arm, open-label extension study to evaluate the
    GlaxoSmithKline, LLC.
  • A 52-week, randomised, double-blind, double-dummy, parallel group, mul
    GlaxoSmithKline, LLC.
  • A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma
    AstraZeneca Pharmaceuticals LP
  • Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
    Sanofi US Services Inc. · Completed · NCT04701983
  • A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler
    AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Allergy & Immunology clinicians in Cincinnati

Sources

NPI registry (CMS NPPES, November 2026; record last updated October 25, 2023), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1558369843. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.